Sugemalimab, an ICI targeting programmed cell death ligand 1 (PD-L1) and a full-length human IgG4 monoclonal antibody, has shown promise in the treatment of G/GEJ adenocarcinoma with PD-L1 combined positive score (CPS) ≥5 (14). The gene discussed is CD274; the disease is gastroesophageal junction adenocarcinoma.